Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PAFSC Committee Approves Reclassification of Tiquizium Bromide and Diclofenac as Class 2 OTC Drugs
March 26, 2013
- Administrative Evaluation: Health Ministry Urged to Review All-Specification Listing Requirement for Generics
March 25, 2013
- LDP Subcommittee Begins Discussions on Amending PAL; Bill Expected to Be Submitted During Current Diet Session
March 25, 2013
- Regulatory Reform Council Not Convinced of MHLW’s Response to Online Sale of OTC Drugs
March 25, 2013
- CSIMC Expert Member Yoshiaki Kamoya (Executive Officer, Shionogi) Says Price Cuts for Long-Listed Drugs and Perpetuation of Premium for New Drug Development Should Be Discussed Together
March 22, 2013
- PMDA’s FY2013 Project Plan OK’d; Discussions for 3rd Mid-Term Plan to Get Underway
March 21, 2013
- Government’s New Office to Compile Health and Medical Strategy by June, Appoints JPMA Teshirogi as Advisor
March 21, 2013
- PMDA Testing New System that Uses Electronic Medical Information to Help Assess Post-Marketing Drug Risk
March 21, 2013
- MHLW Announces 4-Year Extension of Reexamination Period for Adoair
March 21, 2013
- MHLW Issues Notification on Revised GVP, GPSP Ordinances
March 19, 2013
- LDP to Begin Discussions on Bill to Amend PAL; MHLW Aims to Submit Bill during Current Diet Session
March 19, 2013
- Payer Representative Tsuyoshi Kobayashi Questions Automatic Health Insurance Coverage for Additional Indications
March 15, 2013
- Japan Pharmaceutical Association Vice President Hirotsugu Miura Says that 70% Rule for New Generics Will Be Debatable in Future
March 15, 2013
- PAFSC’s Second Committee Recommends Approval for Pfizer’s JAK Inhibitor Xeljanz, Others
March 14, 2013
- LDP Policy Subcommittee Demands Ban on Mixed Healthcare in TPP Talks
March 13, 2013
- MHLW Panel Gives Nod to Electronic Prescribing
March 13, 2013
- MHLW Panel Gives Nod to Electronic Prescribing
March 13, 2013
- MHLW Reports 1st Death Following Quadruple Vaccine Immunization, Causality is Under Investigation
March 13, 2013
- Japan Health Insurance Association President Tsuyoshi Kobayashi Points Out that Price Competition Will Not Work If Prices Are Set Equally
March 12, 2013
- Pricing Rules for Innovative Drugs Will Not Be a Priority in Discussions by Regulatory Reform Council
March 12, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…